Free Trial
NASDAQ:KRBP

Kiromic BioPharma 3/18/2024 Earnings Report

Kiromic BioPharma EPS Results

Actual EPS
-$4.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Kiromic BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kiromic BioPharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Kiromic BioPharma Earnings Headlines

Buffett’s Next Move Could Shock Wall Street
In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.
Kiromic BioPharma Files for Chapter 7 Bankruptcy
See More Kiromic BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiromic BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiromic BioPharma and other key companies, straight to your email.

About Kiromic BioPharma

Kiromic BioPharma (NASDAQ:KRBP), a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

View Kiromic BioPharma Profile

More Earnings Resources from MarketBeat